Puma Biotechnology Inc. Stock
€2.26
Your prediction
Puma Biotechnology Inc. Stock
Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Pros and Cons of Puma Biotechnology Inc. in the next few years
Pros
Cons
Performance of Puma Biotechnology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Puma Biotechnology Inc. | 1.320% | 4.718% | -7.365% | -21.252% | -42.023% | -61.666% | -77.821% |
| Evolus Inc | -3.360% | 5.109% | 20.000% | 68.421% | 59.116% | 114.925% | - |
| Ardelyx Inc. | -3.940% | -1.625% | 0.453% | 36.215% | -7.855% | 371.327% | 20.280% |
| Coherus Bioscien. | 1.760% | -20.402% | -16.557% | -77.568% | -68.750% | -93.667% | -95.188% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When it comes to analyzing the financials of Puma Biotechnology, a company operating in the biotechnology and medical research sector, a mixed picture emerges. The financial statements reflect both potential opportunities and significant challenges. The company's balance sheets, cash flow statements, and income statements portray a landscape marked by heavy research and development investments, fluctuating revenues, and notable operational costs. Evaluating the key metrics paints a clearer picture of the strengths and weaknesses that investors should consider.
Puma Biotechnology's total revenue for 2023 stands at approximately $235.64 million, which showcases the company's capacity to generate significant income. The gross profit also reflects positively at around $172.96 million. This indicates that the company is successfully converting revenue into gross profits, even amidst high operational expenses.
With a market capitalization of around $172.94 million, Puma stands as a viable candidate in the biotech industry. This figure can be a reassuring indicator for potential investors regarding stability and market acceptance.
News
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of the
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 5, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Puma Biotechnology Reports Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the